NCT03551249已完成不适用
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- InSightec
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Device and procedure related adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
详细描述
This is a prospective, multi-center, single-arm study to establish the safety and feasibility of BBB (blood brain barrier) disruption along the periphery of tumor resection cavity using the ExAblate Neuro Model 4000 Type 2 (220 kHz) system. For this study, patients will be eligible to enroll in the study prior to beginning the planned adjuvant TMZ chemotherapy phase of treatment. Of note, only patients who are deemed eligible for adjuvant TMZ will be eligible for enrollment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is eligible for adjuvant temozolomide (TMZ) treatment based on the current standard of care.
- •Men or women age between 18 and 80 years, inclusive.
- •Able and willing to give informed consent.
- •Grade IV glioma (GBM)
- •Combined radiation/TMZ treatment is completed based on the prescribed standard of care regimen.
- •Karnofsky rating 70-
- •Able to communicate during the ExAblate BBBD (Blood Brain Barrier Disruption) procedure.
- •Able to attend all study visits (i.e., life expectancy of at least 3 months).
排除标准
- •Patients presenting with the following imaging characteristics:
- •i. Evidence of acute intracranial hemorrhage.
- •The sonication pathway to the tumor involves:
- •i. Extensive scalp sores. ii. Clips or other metallic implanted objects in the skull or the brain (brain implants)
- •The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema).
- •Patients with cerebellar or brainstem tumors.
- •Patients with positive HIV status.
- •Significant depression not adequately controlled with medication and at potential risk of suicide.
- •Patient receiving bevacizumab (Avastin) therapy.
- •Patients receiving treatment with corticosteroid doses greater than dexamethasone 24 mg daily (or equivalent).
- •Patients undergoing other concurrent therapies such as chemotherapy wafers, immunotoxins delivered by convection-enhanced delivery, regionally administered gene and viral therapies, immunotherapies, focal irradiation with brachytherapy, stereotactic radiosurgery, laser interstitial thermotherapy, and tumor treatment fields therapy.
- •Cardiac disease or unstable hemodynamics including:
- •i. Documented myocardial infarction within six months of enrollment. ii. Unstable angina on medication. iii. Congestive heart failure. iv. Left ventricular ejection fraction <50%. v. History of a hemodynamically unstable cardiac arrhythmia. vi. Cardiac pacemaker.
- •Severe hypertension (diastolic BP > 100 on medication).
- •Anti-coagulant therapy, or medications known to increase risk of hemorrhage within washout period prior to treatment.
- •History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage.
- •Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis.
- •History of drug or alcohol use disorder.
- •Active seizure disorder or epilepsy (seizures despite medical treatment).
- •Known sensitivity to gadolinium-based contrast agents.
- •Known sensitivity to DEFINITY® ultrasound contrast agent or perflutren.
- •Contraindications to MRI such as non-MRI-compatible implanted devices.
- •Large subjects not fitting comfortably into the MRI scanner.
- •Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia.
- •Positive pregnancy test (women of childbearing potential).
- •Severely impaired renal function or on dialysis.
- •Cardiac shunt.
- •Subjects with evidence of cranial or systemic infection.
- •Subjects with significant liver dysfunction, e.g., history of cirrhosis or active hepatitis.
结局指标
主要结局
Device and procedure related adverse events
时间窗: Throughout the study, approximately 12 months.
The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE
次要结局
- Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging(At the time of each ExAblate MRgFUS procedure)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard ChemotherapyGlioblastoma MultiformeNCT03712293InSightec9
已完成
不适用
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM PatientsGlioma, MalignantGlioblastomaNCT04998864InSightec3
已完成
1 期
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBMRecurrent GlioblastomaNCT04440358InSightec13
招募中
不适用
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's DiseaseAlzheimer DiseaseNCT03671889InSightec50
已完成
1 期
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin MonotherapyRecurrent GlioblastomaNCT04417088InSightec28